Top Markets
#1 PulseChain PulseChain +45.13%
#2 Fake World Assets Fake World Assets +11.90%
#3 Bitway Bitway +7.77%
#4 eCash eCash +7.33%
#5 Rocket Pool Rocket Pool +6.62%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +6.53%
#7 OPENLOOT OPENLOOT +6.39%
#8 Meteora Meteora +6.35%
#9 Velvet Velvet +5.88%
#10 Tornado Cash Tornado Cash +5.72%
Coin of the day
PulseChain PulseChain
Settings
Language
ENGLISH
Currency
USD
Theme
LAUNXP Biomedical Co., Ltd LAUNXP Biomedical Co., Ltd

LAUNXP Biomedical Co., Ltd

6876
Rank in Stocks #28267
LAUNXP Biomedical Co. Ltd. specializes in developing innovative pharmaceutical... LAUNXP Biomedical Co. Ltd. specializes in developing innovative pharmaceutical treatments for various types of cancer. Their product line includes therapies designed to combat tumor growth and inhibit cell proliferation, notably utilizing advanced platforms such as virus-like nanoparticles and other nanoparticle-based drug delivery systems. The company was established on September 24, 2015, and its primary corporate operations are based in Taichung, Taiwan.
Share Price
$0.3958979
Market Cap
$27.40M
Change (1 day)
-0.40%
Change (1 year)
-48.96%
Country
TW
Trade LAUNXP Biomedical Co., Ltd (6876)

Category

Healthcare
Revenue for LAUNXP Biomedical Co., Ltd (6876)
Revenue in Aug 2026 TTM: 0
According to LAUNXP Biomedical Co., Ltd latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for LAUNXP Biomedical Co., Ltd from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH